Market intelligence, trend analysis and forecasts for the Pharma and Healthcare industries across the regions

Industry / Poland

Downward Revision To 2012 Drug Market Outlook

July 2012 | Industry Trend Analysis

BMI View: Despite a downgrade to our 2012 growth projections for Poland's pharmaceutical market and a less bullish long-term view on the zloty against the US dollar and euro, we continue to have a positive view of the Polish drug market. Despite the short-term challenges the market remains attractive over the medium term, as one of Central Europe's larger markets the combination of positive demographics and economic growth will be a driver of growth. Over a longer time period, the government's aggressive downward pressure on drug reimbursement expenditure will be reduced despite continued measures to decrease spending in the medium term.

To read the full article, please choose one of the following options:

Subcribers please log in

Emerging Europe InsightEmerging Europe Channels Emerging Europe Countries